Clinical protocol

Hewitt, Allison
November 1997
Pharmaceutical Executive;Nov97, Vol. 17 Issue 11, p108
Trade Publication
Reports on the policies implemented by the US Food and Drug Administration that could alter the way pharmaceutical companies conduct clinical trials, which includes financial disclosure of clinical investigators, submission of more specific adverse event reports and international harmonization guidelines.


Related Articles

  • Dateline Washington. Coorsh, Richard // Consumers' Research Magazine;Dec94, Vol. 77 Issue 12, p6 

    Reports that the Food and Drug Administration has proposed new regulations intended to make clinical trials safer. Provision of the details of safety monitoring plan; Supplement health claims.

  • FDA guidelines on race and ethnicity: obstacle or remedy? Schultz, James // JNCI: Journal of the National Cancer Institute;3/19/2003, Vol. 95 Issue 6, p425 

    Reports on the U.S. Food and Drug Administration's issuance of guidelines calling for the establishment of more detailed race and ethnicity categories in the collection of effectiveness and safety data during clinical trials of promising pharmaceuticals. Substantial differences in responses to...

  • FDA Issues New Safety Guidelines.  // BioWorld Today;10/4/2010, Vol. 21 Issue 191, p5 

    The article reports on the final rule issued by the U.S. Food and Drug Administration (FDA) on what safety information must be reported during drug trials.

  • In-home drug abuse tests require trials. James G., Dickinson // Medical Marketing & Media;Oct97, Vol. 32 Issue 10, p32 

    Reports on the US Food and Drug Association's requirement of clinical trial testing before it approves any consumer in-home test kit for drugs of abuse.

  • Audits citing more deficiencies. Horowitz, Arthur M. // Ophthalmology Times;11/6/95, Vol. 20 Issue 43, p19 

    Discusses the deficiencies in the Food and Drug Administration's (FDA) auditing of institutional review boards (IRB) through its Division of Scientific Investigation, Institutional Review Branch. Review of FDA audit results and related IRB policie s and practices; Regulatory or administrative...

  • US FDA streamlines safety reporting in clinical trials.  // Reactions Weekly;6/18/2011, Issue 1356, p2 

    The article reports that Doctor Rachel Behrman Sherman and colleagues from the U.S. Food and Drug Administration (FDA) claim that the new FDA regulation on safety reporting in clinical trials will improve patient safety and provide better data to support clinical decision making.

  • Public hearing on financial disclosure by clinical investigators. Nightingale, Stuart L. // JAMA: Journal of the American Medical Association;6/28/95, Vol. 273 Issue 24, p1897 

    Reports that the US Food and Drug Administration will convene a public meeting on July 20, 1995 to obtain additional comments and information on the agency's proposed regulation on financial disclosure by clinical investigators. Publication of the proposed regulations in the September 22, 1994...

  • FDA plans more inspections of gene therapy trials.  // Urology Times;Mar2000, Vol. 28 Issue 3, p3 

    Reports on the plans of the United States Food and Drug Administration to step up inspections during the Investigational New Drug phase of gene therapy trials.

  • Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance.  // Health & Quality of Life Outcomes;2006, Vol. 4, p79 

    This guidance describes how the FDA evaluates patient-reported outcome (PRO) instruments used as effectiveness endpoints in clinical trials. It also describes our current thinking on how sponsors can develop and use study results measured by PRO instruments to support claims in approved product...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics